CFF provided the following clinical trial update on 12/7/2016:
Phase 2 study of CTP-656 in adults with CF who are currently taking ivacaftor (Kalydeco®)
Description: This study is taking place at multiple care centers across the U.S. It will look at the safety and effectiveness of the drug CTP-656 in adults with CF who have a gating mutation and are currently taking ivacaftor (Kalydeco®).
Age: 18 Years and Older
Mutation: One Copy F508del or No Copies F508del
Fev1% Predicted: 60 to 90%
Number of Visits: 6
Length of Participation: 7 weeks
ClinicalTrials.gov link: https://clinicaltrials.gov/ct2/show/NCT02971839